Episode 29, “Bayesian Clinical Trials with Frank Harrell”
Prof. Frank Harrell, a leading figure in Bayesian biostatistics and experienced FDA advisor, joins Dr. Scott Berry on "In the Interim…" for an unfiltered assessment of statistical barriers and regulatory realities shaping clinical trial design.
Prof. Harrell addresses the slow adoption of Bayesian approaches within the clinical trial community, critical flaws in type 1 error fixation, and the value of longitudinal and ordinal outcome modeling. Harrell describes both the influence of Dr. Don Berry and the ongoing effort to guide U.S. regulatory frameworks.
Listen to this fascinating conversation today to learn more about the Bayesian approach to clinical trials: https://www.berryconsultants.com/resource/29-bayesian-clinical-trials-with-frank-harrell